Page last updated: 2024-12-08

osemozotan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

osemozotan: 5-HT(1A) receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID198747
CHEMBL ID1742408
SCHEMBL ID1548269
MeSH IDM0578076

Synonyms (14)

Synonym
mn-305
osemozotan
osemozotan [inn]
unii-m65825806q
137275-81-1
m65825806q ,
3-(1,3-benzodioxol-5-yloxy)-n-(((2s)-2,3-dihydro-1,4-benzodioxin-2-yl)methyl)propan-1-amine
5-(3-((2s)-(1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol
CHEMBL1742408
SCHEMBL1548269
DTXSID90160127
mkc 242;mkc-242;mkc242
osemozotan (hydrochloride)
(s)-3-(benzo[d][1,3]dioxol-5-yloxy)-n-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)propan-1-amine

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (32.26)18.2507
2000's17 (54.84)29.6817
2010's4 (12.90)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.19 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]